Patheon Signs Strategic Agreement with Grünenthal
PTSM: Pharmaceutical Technology Sourcing and Management
Patheon will assist in the development of INTAC, a technology designed to reduce the abuse of controlled substances.
On Feb. 22, 2016 Patheon announced it has signed a strategic agreement with Grünenthal, an international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s abuse deterrent formulation technology INTAC.
Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. INTAC is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances.
INTAC is an abuse-deterrent formulation technology platform, used with several FDA-approved opioid products. As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site.
Source: Patheon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
